Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusionAstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) ...

Within the 48-week treatment window, the Bruton’s tyrosine kinase (BTK) inhibitor triggered a 57.1% improvement in patients’ ...

Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -- Zenas acquired the ...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were ...

A new study examined whether routine blood test measures could help in identifying disease flares in people with systemic ...

A common virus carried by most humans could trigger lupus, offering new clues for preventing and treating this dangerous ...

A recent review published in Current Molecular Pharmacology explores the therapeutic potential of melatonin in systemic lupus ...

In lupus patients, latent Epstein-Barr virus can reprogram B cells and send the body’s immune response into overdrive, resulting in widespread inflammation. The Epstein-Barr virus (EBV) has been ...

A recent review published in Current Molecular Pharmacology explores the therapeutic potential of melatonin in systemic lupus ...

AN understanding of the interrelations of pregnancy and systemic lupus erythematosus is of considerable clinical importance, particularly since the disease occurs most frequently in women during the ...

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on ...